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Abstract 
Background: Primary hyperparathyroidism is one of the most common causes of hypercalcemia. Inherited forms 
of primary hyperparathyroidism like Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, 
Hyperparathyroidism-Jaw Tumor Syndrome or isolated familial tumors are not common for our population.
Results: We present a case of primary hyperparathyroidism in a 38-year-old Turkish man with hyperaldosteronism 
(Conn’s syndrome).
Conclusion: Genetic studies could not reveal any mutation. We could not identify any inherit form of the diseases. 
We wanted the first-line relatives examination of the suspected gene mutation, but they refused.
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Background
Primary hyperparathyroidism is usually diagnosed inci-
dentally, few patients have overt signs or symptoms of 
the classic disease, therefore the disease considered to be 
asymptomatic. Hypercalcemia and high levels of serum 
Parathyroid hormone are typical findings. Neck ultra-
sound and parathyroid scintigraphy are generally used for 
diagnosis of parathyroid adenoma [1].
Primary hyperaldosteronism, which in 65% is caused 
by aldosterone-secreting adenoma (Conn syndrome), is 
one of the reasons of endocrine hypertension [2]. Associ-
ation of both tumors was reported rarely [3, 4]. We aimed 
to re-discuss Primary Hyperparathyroidism, Primary 
Hyperaldosteronism and Multiple Endocrine Neoplasia 
syndromes in the light of the findings of this rare case.
Case presentation
A 38-year-old Turkish male was admitted to our outpa-
tient clinic for hypercalcemia. Before entering our clinic, 
hypercalcemia has been detected in another medical 
center. History revealed, that he took ace inhibitor in 
combination with thiazide diuretic for hypertension. Due 
to the complications, like hypopotassemia this medicine 
was replaced with calcium channel blockers. In his fam-
ily history, none of his first degree relatives had hyperten-
sion. His father died at 47 years of age due to biliary tract 
cancer. His three children were diagnosed with West 
Syndrome. One of them died at the age of 13  months, 
while the other 9 months of age. His third child is 2 years 
old and living with the respiratory support equipment. 
He also has a 13-year-old healthy son. There is no other 
significant clinical data in his medical history.
On his physical examination: blood pres-
sure—150/90  mmHg, pulse −74 per minute, rhythmic. 
His general clinical appearance was good. The other 
systemic and laboratory findings were the following: 
complete blood count and thyroid function tests were 
normal: serum Ca level: 10.9  mg/dl (8.8–10.2), inor-
ganic P: 2.4 mg/dl (2.7–4.5), Mg: 2.3(1.6–2.6), albumine: 
3.9  g/dl, parathormone (PTH): 200  pg/ml (12–88), Na: 
138 mmol/l, K+: 2.8 mmol/l, glucose: 85 mg/dl, creatinine: 
0.84  mg/dl, alanine transaminase: 24  U/l, white blood 
cells 8 ML, hemoglobin 14  g/dl, platelet 219 C-reactive 
protein 0.4  mg/dl (0–0.8), alkaline phosphatase 61  U/l 
(38–126), 25-OH vitamin D3 22 ng/ml (14–66). Calcium 
level in 24-h urine: 251 mg/day, inorganic P: 88 mg/day, 
and K+ value in spot urine: 66 mmol/l. Aldosterone level 
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was measured after normalization of his serum potas-
sium level (result: 26.9 ng/dl). Plasma renin activity was 
<0.15  ng/ml/h. The patient was detected for multiple 
endocrine neoplasia syndromes. Levels of catecholamine 
and its metabolites in 24-h urine were normal. In the low 
dose (1 mg) dexamethasone suppression test, serum cor-
tisol level was suppressed to the normal range. Serum 
prolactin, thyroid-stimulating hormone, adrenocortico-
tropic hormone, growth hormone, insulin-like growth 
factor 1 and calcitonin were normal.
Thyroid ultrasound revealed a 24  ×  14  ×  12.5  mm 
hypoechoic nodular lesion at the upper posterior part 
of the right thyroid lobe, within the thyroid capsule 
(intrathyroidal parathyroid adenoma?). MIBI (Tech-
netium (99mTc) sestamibi) scintigraphy of parathy-
roid glands was consistent with the ultrasound finding. 
Abdominal magnetic resonance imaging revealed 1.6 cm 
adrenal gland mass consistent with adenoma, cystic 
lesions in both kidneys with the largest (3 cm in length) 
in the right kidney and also on this side 11  mm lesion 
which may be consistent with angiomyolipoma. Pituitary 
magnetic resonance imaging was normal.
The patient was operated for parathyroid adenoma. 
At the 3rd day after the operation, serum Ca level was 
found to be 9.5 mg/dl, inorganic P—3.6 mg/dl and para-
thyroid hormone—62  pg/ml. Pathological examination 
of the surgery material revealed parathyroid adenoma. 
The patient post operatively was followed during the 
2 months with spironolactone therapy for his hyperten-
sion. This medication was stopped soon after, due to its 
side effects like erectile dysfunction. Post-surgery, which 
was conducted for the lesion (1.6  cm) identified on the 
left adrenal gland revealed adrenal aldosterone produc-
ing adenoma. Follow up the adrenal surgery, his blood 
pressure came to normal ranges and hypokalemia were 
improved. Blood potassium and calcium levels were 
within normal ranges. Genetic screening revealed nega-
tive mutation of MENIN gene.
Discussion
In 25 % of the sporadic parathyroid adenoma, deletion is 
present on the 11th chromosome and is caused by inac-
tivating mutations in the tumor suppressor gene encod-
ing menin. Although Multiple Endocrine Neoplasia Type 
1 includes tumors of the parathyroid, anterior pituitary, 
and pancreatic islets, the parathyroid tumors are far 
more prevalent than the others; 95% of affected patients 
eventually develop hyperparathyroidism. In the litera-
ture, adrenal adenomas are seen in 25–40%. 95% of the 
multiple endocrine neoplasia cases occur before 45 years 
of age [5]. Our patient was 38 years old and association 
of parathyroid adenoma and Conn syndrome, but his 
family history were not any findings suggesting multi-
ple endocrine neoplasia. We suspected that this may be 
sporadically developed syndrome, however the genetic 
investigation did not reveal the MENIN gene mutation 
(Additional file 1).
We looked for other similar cases in the clinical lit-
erature. You Lim detected Hurthle cell thyroid cancer 
and meningioma of the brain in addition to parathyroid 
adenoma and Conn syndrome presented with left adre-
nal adenoma in a 68-year-old female patient. In this case 
Ca was 11.6 mg/dl, K+ 1.8 mmol/l, parathyroid hormone 
82 pg/ml [6].
Carmela also reported a case with both primary hyper-
parathyroidism and primary aldosteronism (Conn syn-
drome). She described the case of 68-year-old female 
with primary aldosteronism with left adrenal adenoma 
(3 cm in length), and parathyroid adenoma as well. (Ca: 
11.2  mg/dl, parathyroid hormone: 240  pg/ml). Similar 
to our patient, after the surgery, hypertension, serum Ca 
and K+ levels were normalized [7].
In our case, screening for MENIN gene mutation was 
negative, so we did not consider multiple endocrine neo-
plasia syndrome.
Conclusion
The genetic studies have failed to show the expected gene 
mutation. We could not identify any known inherit form 
of the disease. Given the rarity of the disease, we decided 
to examine the patient first-line relatives, but they 
refused. In conclusion, primary hyperparathyroidism and 
primary aldosteronism (Conn syndrome) can be seen 
together in clinical practice and proper management can 
guarantee a solid compensation.
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